Clearside Biomedical Featured in Multiple Data Presentations at the 44th Virtual Annual Macula Society Meeting
Clearside Biomedical Featured in Multiple Data Presentations at the 44th Virtual Annual Macula Society Meeting Proprietary suprachoroidal injection platform demonstrates broad applicability across multiple retinal disorders CLS-AX will also be featured at the upcoming virtual Angiogenesis, Exudation, and Degeneration 2021 conference on February 13, 2021 Clearside Biomedical, Inc. , a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of … – Proprietary suprachoroidal injection platform demonstrates b...
Source: investingnews.com